ClinicalTrials.gg
CompletedNCT00788034Updated Jun 23, 2015

Relapse-prevention Study With Lu AA21004 (Vortioxetine) in Patients With Generalized Anxiety Disorder

A Phase 3 interventional study of Lu AA21004 and Placebo in Generalized Anxiety Disorder, sponsored by H. Lundbeck A/S. Completed at 81 sites in 11 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-06-23.

Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
459
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The study will evaluate the long-term maintenance of efficacy of Lu AA21004 in patients with Generalized Anxiety Disorder (GAD) who responded to acute treatment with Lu AA21004.

Read the detailed description

GAD is a common and disabling mental disorder associated with substantial medical and psychiatric comorbidity and occupational impairment. It is characterized by inappropriate or excessive anxiety and worrying that persists over time for more than six months. Common features include apprehension, with worries about future misfortune; inner tension and difficulty in concentrating; motor tension, with restlessness, tremor and headache; and autonomic anxiety symptoms, with excessive perspiration, dry mouth and epigastric discomfort. GAD is typically a chronic disorder with a high relapse rate and therefore requires effective long-term treatment. Long-term studies are necessary to demonstrate that the short-term effect is maintained.

02

Conditions studied

  • Generalized Anxiety Disorder

Keywords

  • Relapse prevention
  • GAD
  • Maintenance
  • Double-blind
  • Multicentre
03

In context

Generalized Anxiety Disorder

518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.

This study's enrollment of 459 is above the median of 83 across 440 interventional studies indexed under Generalized Anxiety Disorder.

Browse Generalized Anxiety Disorder studies →

Lead sponsor

H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The patient has GAD as the primary diagnosis according to criteria (classification code 300.02).

  • The patient has a HAM-A total score >=20 at screening and baseline visits
  • The patient has a HAM-A score >=2 on both Item 1 (anxious mood) and Item 2 (tension) at screening and baseline visits
  • The patient has a MADRS total score \<=16 at screening and baseline visits

Exclusion criteria

Exclusion Criteria:

  • Any current psychiatric disorder other than GAD as defined in the (assessed with the MINI)
  • Any substance disorder (except nicotine and caffeine) within the previous 6 months as defined in the DSM-IV-TR
  • Women of not using effective

Other protocol-defined inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
459 participants (actual)

Study arms

  • Experimental
    Lu AA21004

    Drug: Lu AA21004

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • 5 or 10 mg/day

    Also known as: Vortioxetine

  • DrugPlacebo

    Once daily

06

What researchers measure

Primary outcomes

  1. Time to relapse

    Time frame: At least 24 weeks

Secondary outcomes

  1. Relapse rates, Hamilton Anxiety Rating Scale (HAM-A), Clinical Global Impression Scale (CGI), MOS SF-36, Sheehan Disability Scale (SDS), Adverse events, Clinical laboratory tests, Vital signs, ECG

    Time frame: At least 24 weeks

07

Study locations

81 sites
  • AR010
    Buenos Aires, 1900, Argentina
  • AR012
    Buenos Aires, B1900BHE, Argentina
  • AR002
    Buenos Aires, C1117ABH, Argentina
  • AR008
    Buenos Aires, C1405BOA, Argentina
  • AR003
    Buenos Aires, C1425AHQ, Argentina
  • AR013
    Buenos Aires, C1428AAQ, Argentina
  • AR004
    Cordoba, 5000, Argentina
  • AR015
    La Plata, 1900, Argentina
  • AR006
    Mendoza, M5500BCR, Argentina
  • AR009
    Mendoza, M5502BKH, Argentina
  • AR001
    Santa Fé, S2000QJI, Argentina
  • CL004
    Antofagasta, Chile
  • CL001
    Coquimbo, Chile
  • CL002
    Santiago, Chile
  • CL003
    Santiago, Chile
  • CL005
    Santiago, Chile
  • CL007
    Santiago, Chile
  • CL008
    Santiago, Chile
  • CL006
    Vina del Mar, Chile
  • CO003
    Barranquilla, Colombia
  • CO001
    Bogotá, Colombia
  • CO005
    Bogotá, Colombia
  • CO006
    Envigado, Colombia
  • CO002
    Medellin, Colombia
  • CO007
    Medellin, Colombia
  • CO004
    Pareira, Colombia
  • CR002
    Escazu, Costa Rica
  • CR004
    Guadalupe, Costa Rica
  • CR001
    San José, Costa Rica
  • CR003
    San Pedro, Costa Rica
  • EE001
    Tallinn, 10613, Estonia
  • EE004
    Tallinn, 13517, Estonia
  • EE002
    Tartu, 50417, Estonia
  • FI006
    Espoo, 2650, Finland
  • FI008
    Helsinki, 00260, Finland
  • FI001
    Helsinki, 00530, Finland
  • FI004
    Helsinki, 100, Finland
  • FI011
    Helsinki, 100, Finland
  • FI010
    Helsinki, 99, Finland
  • FI005
    Juväskylä, 40100, Finland
  • FI012
    Kuopio, 70110, Finland
  • FI002
    Oulu, 90100, Finland
  • FI009
    Rauma, 26100, Finland
  • FI003
    Turku, 20100, Finland
  • FI007
    Turku, 20100, Finland
  • FR011
    Arcachon, 33120, France
  • FR010
    Caen, 14000, France
  • FR016
    Douai, 59500, France
  • FR012
    Nantes, 44000, France
  • FR004
    Nîmes, 30029, France
  • FR013
    Palaiseau, 91120, France
  • FR007
    Rennes, 35000, France
  • FR001
    Saint-André-de-Cubzac, 33240, France
  • FR002
    Strasbourg, 67000, France
  • FR015
    Toulouse, 31000, France
  • FR005
    Toulouse, 31200, France
  • HU005
    Budapest, 1036, Hungary
  • HU004
    Budapest, 1095, Hungary
  • HU002
    Budapest, 1135, Hungary
  • HU001
    Gyula, 5700, Hungary
  • HU006
    Nagykallo, 4320, Hungary
  • HU008
    Sopron, 9400, Hungary
  • PE003
    Lima, 27, Peru
  • PE002
    Lima, 41, Peru
  • RU004
    Chita, 672090, Russian Federation
  • RU006
    St. Petersburg, 192019, Russian Federation
  • RU002
    St. Petersburg, 193019, Russian Federation
  • RU003
    St. Petersburg, 193019, Russian Federation
  • RU001
    Tomsk, 634014, Russian Federation
  • ZA006
    Bloemfontein, 9033, South Africa
  • ZA004
    Cape Town, 1, South Africa
  • ZA011
    Cape Town, 7130, South Africa
  • ZA012
    Cape Town, 7130, South Africa
  • ZA003
    Cape Town, 7140, South Africa
  • ZA010
    Cape Town, 7620, South Africa
  • ZA007
    Gauteng, 157, South Africa
  • ZA001
    Gauteng, 2195, South Africa
  • ZA009
    Gauteng, 7500, South Africa
  • ZA002
    Kempton Park, 1620, South Africa
  • ZA008
    KwaZulu Natal, 3630, South Africa
  • ZA005
    Welkom, 9459, South Africa
08

References and documents

Publications

  • Baldwin DS, Loft H, Florea I. Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder. Int Clin Psychopharmacol. 2012 Jul;27(4):197-207. doi: 10.1097/YIC.0b013e3283530ad7. PubMed 22475889 ↗
  • Christensen MC, Loft H, Florea I, McIntyre RS. Efficacy of vortioxetine in working patients with generalized anxiety disorder. CNS Spectr. 2019 Apr;24(2):249-257. doi: 10.1017/S1092852917000761. Epub 2017 Oct 30. Erratum In: CNS Spectr. 2019 Apr;24(2):275. doi: 10.1017/S1092852918000974. PubMed 29081307 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2008, a primary completion of Jun 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2008
First posted
Nov 10, 2008
Start
Oct 2008
Primary completionActual
Jun 2010
CompletionActual
Jul 2010
Last update
Jun 23, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00788034
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Nov 10, 2008
Start date
Oct 2008
Primary completion
Jun 2010
Completion
Jul 2010
Last update
Jun 23, 2015

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@lundbeck.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion